Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma

References

• Toro JR, Travis LB, Wu HJ, et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922–2930.
   PubMed Web of Science ®Google Scholar
• UK CR. Soft tissue sarcoma incidence statistics. 2010. Available from:
   Google Scholar
• NCIN. Liposarcoma: incidence and survival rates in England. 2013. Available from: http://www.ncin.org.uk/publications/data_briefings/liposarcoma_incidence_and_survival_rates_in_england
   Google Scholar
• Italiano A, Toulmonde M, Cioffi A, et al. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol. 2012;23(6):1601–1607.
   PubMed Web of Science ®Google Scholar
• Lee ATJ, Thway K, Huang PH, et al. Clinical and molecular spectrum of liposarcoma. J Clin Oncol. 2018;36(2):151–159.
   PubMed Web of Science ®Google Scholar
• Dangoor A, Seddon B, Gerrand C, et al. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res. 2016;6:20.
   PubMed Web of Science ®Google Scholar
• MacNeill AJ, Miceli R, Strauss DC, et al. Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: a report from the Trans-Atlantic RPS working group. Cancer. 2017;123(11):1971–1978.
   PubMed Web of Science ®Google Scholar
• Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–423.
   PubMed Web of Science ®Google Scholar
• Colia V, Fumagalli E, Provenzano S, et al. High-dose ifosfamide chemotherapy in a series of patients affected by myxoid liposarcoma. Sarcoma. 2017;2017:3739159.
   PubMedGoogle Scholar
• Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34(8):786–793.
   PubMed Web of Science ®Google Scholar
• Schoffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629–1637.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Schoffski P, Grignani G, et al. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol. 2017;35(30):3433–3439.
   PubMed Web of Science ®Google Scholar
• Dickson MA, Schwartz GK, Keohan ML, et al. Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial. JAMA Oncol. 2016;2(7):937–940.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov UNLoM. A study assessing efficacy & safety of ribociclib in patients with advanced well/dedifferentiated liposarcoma. 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03096912
   Google Scholar
• ClinicalTrials.gov UNLoM. Study of abemaciclib in dedifferentiated liposarcoma. 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT02846987
   Google Scholar
• Jones RL, Fisher C, Al-Muderis O, et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur j cancer. 2005;41(18):2853–2860.
   PubMed Web of Science ®Google Scholar
• Livingston JA, Bugano D, Barbo A, et al. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Sci Rep. 2017;7(1):11836.
   PubMedGoogle Scholar
• Italiano A, Garbay D, Cioffi A, et al. Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy. Ann Oncol. 2012;23(8):2205–2206.
   PubMed Web of Science ®Google Scholar
• van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–1886.
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126–3132.
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Judson IR, Benson C, et al. Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study(). Acta Oncol. 2017;56(12):1769–1775.
   PubMed Web of Science ®Google Scholar
• Woll P, Gaunt P, Judson I, et al. Axi-STS: an NCRI Sarcoma Clinical Studies Group phase II trial of the VEGFR inhibitor axitinib in advanced soft tissue sarcoma (STS). NCRI. 2014; Liverpool. editors.
   Google Scholar
• Mahmood ST, Agresta S, Vigil CE, et al. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer. 2011;129(8):1963–1969.
   PubMed Web of Science ®Google Scholar
• Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res. 2018;24(21):5233–5238.
   PubMed Web of Science ®Google Scholar
• Mir O, Brodowicz T, Italiano A, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(12):1732–1742.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–731.
   PubMed Web of Science ®Google Scholar
• Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 2010;15(6):539–547.
   PubMed Web of Science ®Google Scholar
• Verheijen RB, Beijnen JH, Schellens JHM, et al. Clinical pharmacokinetics and pharmacodynamics of pazopanib: towards optimized dosing. Clin Pharmacokinet. 2017;56(9):987–997.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15(12):4220–4227.
   PubMed Web of Science ®Google Scholar
• Li H, Wozniak A, Sciot R, et al. Pazopanib, a receptor tyrosine kinase inhibitor, suppresses tumor growth through angiogenesis in dedifferentiated liposarcoma xenograft models. Transl Oncol. 2014;7(6):665–671.
   PubMed Web of Science ®Google Scholar
• Kiyuna T, Murakami T, Tome Y, et al. Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model. Tissue Cell. 2018;53:30–36.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Dowlati A, Savage S, et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. 2005;23(16_suppl):3012.
   Google Scholar
• Samuels BL, Chawla SP, Somaiah N, et al. Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Cancer. 2017;123(23):4640–4647.
   PubMed Web of Science ®Google Scholar
• Valverde CM, Broto JM, Lopez-Martin JA, et al. Phase II clinical trial evaluating the activity and tolerability of pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) Study—NCT01692496. 2016;34(15_suppl):11039.
   Google Scholar
• Grünwald V, Kunitz A, Schuler MK, et al. Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): results of a phase II study (EPAZ). 2018;36(15_suppl):11506.
   Google Scholar
• Nakamura T, Matsumine A, Kawai A, et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer. 2016;122(9):1408–1416.
   PubMed Web of Science ®Google Scholar
• Agarwal M, Thareja N, Benjamin M, et al. Tyrosine kinase inhibitor-induced hypertension. Curr Oncol Rep. 2018;20(8):65.
   PubMed Web of Science ®Google Scholar
• Pinkhas D, Ho T, Smith S. Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development. Cardiooncology. 2017;3.
   PubMedGoogle Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–1068.
   PubMed Web of Science ®Google Scholar
• Kapadia S, Hapani S, Choueiri TK, et al. Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol. 2013;52(6):1202–1212.
   PubMed Web of Science ®Google Scholar
• Agulnik M, Mohindra NA, Milhem MM, et al. A phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. 2018;36(15_suppl):11550.
   Google Scholar
• ClinicalTrials.gov UNLoM. Gemcitabine hydrochloride with or without pazopanib hydrochloride in treating patients with refractory soft tissue sarcoma. 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT01532687
   Google Scholar